middle.news
How Cleo Diagnostics’ Alpha Test Could Transform Ovarian Cancer Diagnosis
2:45am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
How Cleo Diagnostics’ Alpha Test Could Transform Ovarian Cancer Diagnosis
2:45am on Monday 2nd of June, 2025 AEST
Key Points
Alpha testing completed on commercial prototypes with 120 blood samples
Assay kits demonstrated robust, reproducible performance meeting design specifications
Confirmed ability to distinguish benign from malignant ovarian disease
Next phase includes assay optimisation, beta testing, and manufacturing scale-up
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cleo Diagnostics (ASX:COV)
OPEN ARTICLE